DUBLIN, Dec. 17, 2013 /PRNewswire/ — Research and Markets (http://www.researchandmarkets.com/research/3prf9w/cardiac_marker) has announced the addition of the „Global Cardiac Marker Diagnostic Testing Market Report” report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

Cardiac marker diagnostic testing measures the concentration of certain proteins, i.e., biomarkers, which indicate the presence or severity of cardiovascular disease (CVD). Among the most prevalent CVDs are sudden cardiac arrest (SCA), acute myocardial infarction (AMI), congestive heart failure (CHF) and atherosclerosis. Every year, an estimated 17 million people worldwide die from a CVD.

This report describes the specific market segment of the in vitro diagnostics (IVD) market devoted to cardiac marker testing, including size; growth; industry trends; product development and investment; and clinical measurement devices, reagents and supplies. Highly-attractive cardiac marker areas of growth covered in this review include: the cardiac rapid assay market, troponins, Creatine kinase-myocardial band (CK-MB) and brain natriuretic peptide (BNP) testing. Also examined are heart failure, myoglobin, homocysteine (Hcy), C-reactive protein (CRP), pulmonary embolism (PE) (D-dimer test), low-density and high-density lipoproteins (LDL and HDL), stroke, cardiac enzymes, albumin, cardiac markers used in clinical decisions, cardiac markers in renal failure, cardiac panels and point of care (POC) cardiac markers.

This study also provides a thorough analysis of the companies known to be marketing, manufacturing or developing cardiac marker products in the U.S. and worldwide, as well as detailed tables, charts and figures covering the U.S., Europe and Asia markets.

Key Topics Covered:

1. Overview

2. Introduction

3. Cardiac Marker Testing Markets: Market Segment Analysis: Size, Growth and Share

4. Cardiovascular Disease Markers
4.1 Cholesterol, HDL and LDL
4.2 Homocysteine
4.3 Fibrinogen
4.4 C-Reactive Protein
4.5 Lipoprotein Fractions
4.6 Pulmonary Embolism (D-Dimer Test)
4.7 Oxidized LDL and HDL
4.8 Stroke

5. Cardiac Marker Testing Development Issues
5.1 Genetic Testing and Personalized Medicine
5.2 Preventive Medicine
5.3 Patient Safety and Quality Measures
5.4 Reimbursement
5.5 Cardiovascular
5.6 Screening for Diabetes
5.7 Other Reimbursement Concerns
5.8 CPT Test Codes and Payment Amounts
5.9 Rapid Near-Patient Testing in Hospitals
5.10 Satellite Facilities
5.11 Regionalization of Laboratory Care
5.12 Requirements for POCT
5.13 Clinical Laboratory Improvement Amendments (CLIA)
5.14 Regulatory Requirements
5.15 Record-keeping and Data Management

6. Business Trends in the Industry
6.1 Sector Consolidation
6.2 Diagnostic Testing Growth Trends
6.3 Acquisition, License Agreements, Internal Development and Partnerships
6.4 Product Testing Depth in Cardiac Marker Testing
6.5 Government Regulation
6.6 Barriers to Growth
6.7 Drivers of Growth

7. Important Technology Trends
7.1 Cardiac Biomarker Research
7.2 Potential Stroke Markers
7.3 Future Developments for Cardiovascular Markers
7.4 Research Questions
7.5 Lp-PLA2
7.6 Urotensin

8. Company Profiles

Companies Mentioned:

• Abbott Laboratories
• Alere
• Ani Biotech
• Axis-Shield
• Bayer Corporation
• Beckman Coulter (now part of Danaher)
• Biosite, Inc. (now a brand of Alere)
• Johnson & Johnson
• LifeSign
• PreMD, Inc.
• Randox Laboratories
• Response Biomedical
• Roche Diagnostics
• Siemens Healthcare Diagnostics (f/k/a Bayer Healthcare Diagnostics, Diagnostic Products Corporation, and Dade Behring)
• Sierra Resources International
• Spectral Diagnostics, Inc.

For more information visit http://www.researchandmarkets.com/research/3prf9w/cardiac_marker

Media Contact: Laura Wood , +353-1-481-1716, [email protected]